Novartis Stopping Work on Branaplam as Oral SMA Therapy & 31 Days of SMA
Aug 04, 2021, 12:00 AM
SMA News Today’s multimedia associate, Price Wooldridge, discusses Novartis stopping work on the development of Branaplam as an oral treatment for Spinal Muscular Atrophy (SMA).
Forums Director Kevin Schaefer reads a story from our 31 Days of SMA series. This piece, written by Alvaro Cheherlian, is about being an entrepreneur with SMA.
Link to 31 Days of SMA series: https://smanewstoday.com/category/31-days-of-sma/
Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/